Clinical Trial Update: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ARRY-520 in relapsed or refractory multiple myeloma completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• ARRY-520 (indisulam)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma, Plasma Cell Leukemia | Phase 1, Phase 2 | Status: COMPLETED